Faculty of Medicine, Universitas Indonesia
Jakarta Pusat, DKI Jakarta, 10430, Indonesia
NCT Number: NCT03455049
Prevalence of type 2 diabetes have been increased, but medications had not been well, so that needed new alternatives. A new approach used in management of type 2 diabetes is incretin based therapy. Incretin hormone, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotrophic peptide (GIP), had producted in intestine due to carbohydrate intralumen. After had secreted, GLP-1 had degradated by DPP-4 enzyme till number and effect had been decreased. Decreasing of GLP-1 effect as main defect in type 2 diabetes.
Andrographis paniculata (A. paniculata) as traditional treatment had known since years ago to have hypoglycemia effect. Extract of A. paniculata consists of andrographolid and flavonoid. Based on study of Wooten et al that flavonoid has hydroxyl to stimulate insulin's production through modulated GLP-1 receptor (GLP-1 receptor ligand). So the investigators need to study about The Effect of A. paniculata Extract to GLP-1, Fasting Plasma Insulin, Insulin concentrations measured during a standardized 2-h OGTT, and HOMA-IR.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Jakarta Pusat, DKI Jakarta, 10430, Indonesia
Blood's participants will be examined fasting plasma insulin and glycated albumin (from fasting blood) and insulin measured during a standardized 2-h OGTT, DPP-4 enzyme, and GLP-1 (from standardized 2-h OGTT blood). Then, complete urinalysis test. Participants will be randomized to be two groups are group have been intervenced by capsules of A. paniculata or group placebo. Each group will be explained about procedure to consume capsules A. paniculata or placebo for 14 days, storage procedures, and the way to contact the investigators if adverse event happened. The investigators will contact participants to remember the schedule to consume capsules A. paniculata, ask whether the side effects or not, and ask the result of self monitoring blood glucose every three days by glucose meter have been given.
Before day 12th, participants will be contacted to come in visit 2nd. In visit 2nd (day 15th) will be done anamneses, assessment of compliance, reporting adverse event and side effect, physical examination, fasting plasma glucose test, fasting insulin, HOMA-IR, GA and complete urinalysis. Then, will be done standardized 2-h OGTT. Two hours later, it will be done plasma glucose level, insulin, DPP-4 enzyme, and GLP-1. Participants will be explained that they will not receive capsules of A. paniculata for 7 days (day 15th till 21th). This is called wash out.
Participants will be explained about procedures to consume capsule of A. paniculata or placebo in day 22th till 35th. Before day 32th, participants will be contacted to come in visit 3rd (day 36th). In visit 3rd, will be done anamneses, assessment of compliance, reporting adverse event and side effect, physical examination, fasting plasma glucose test, fasting insulin, HOMA-IR, GA and complete urinalysis. Then, will be done standardized 2-h OGTT. Two hours later, it will be done plasma glucose level, insulin, DPP-4 enzyme, and GLP-1.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes incretin effect
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes beta-cell secretion
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes beta-cell secretion after 2h-OGTT
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index of insulin resistance
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes beta-cell function
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes beta-cell function after 2h-OGTT
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes degradation of GLP-1 in Ileum
Time frame: A measure assesing change from baseline GLP-1 at 14 days.
Index analyzes plasma glucose during 2 weeks
Indonesia University
Other
The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR in Normal and Prediabetes Subject
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT05764200
Glucose Metabolism Disorders, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Maastricht, Netherlands
View Trial DetailsNCT05724134
Body Weight, Diabetes Mellitus
New York, United States
View Trial DetailsNCT05729282
Diabetes Mellitus, Digestive System Diseases
New York, United States
View Trial Details